Neith Corporation (6236) fair value: what the stock is really worth
As of Nov 12, 2026: fair value (intrinsic value) of Neith Corporation stock TWD 4.59, price TWD 13.55, that is 66.1% below the price, quality 75 out of 100. Rating: strongly overvalued. Calculated from audited financials with 18 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range 8.12 TWD – 37.80 TWD · fair‑value band 4.29 TWD – 4.90 TWD · the 13.55 TWD price screens above the 4.59 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Neith in your weekly email
Every Wednesday you see whether Neith is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company provides nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name.
Show moreShow less
It also offers genetic testing services. In addition, the company offers energy and dual-purpose mattresses, energy masks, energy silicon gel necklaces, energy waistbands, energy heating stones, massage rods, and water purifiers, as well as Ganbanyoku, an energy stone spa bed.
Further, it offers beauty care products, such as cell regeneration and rejuvenation series skin care products; home energy products; and microcontrollers and peripherals.
Neith Corporation was formerly known as Come True Biomedical Inc. Neith Corporation was incorporated in 1997 and is based in Taichung, Taiwan.
Stock analysis
Neith Corporation (6236) currently trades at 13.55 TWD, while our model-based Fair Value estimate is 4.59 TWD, 66% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 6.01 TWD per share, and 1 of the 18 models we run sit above the 13.55 TWD price.
Bear case: the Earnings-Based group reads lowest at 0.7500 TWD, and 17 of the 18 models stay below the price. Data coverage for this calculation is low.
Scenario range: 4.29 TWD (bear) to 4.90 TWD (bull), the price of 13.55 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 75/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Neith Corporation reported revenue of 36.1M TWD in FY2025 versus 31.4M TWD in FY2021, a compound +3.6%/yr. Reported net income was 3.2M TWD in FY2025.
Key figures
Market cap 564M TWD (≈ $17.1M) Micro · P/S ratio 22.0 · EPS (TTM) 0.0100 TWD · Net margin 1.0% · Return on equity 0.2% · Return on assets (EBIT) −13.0% (5-year average) · Operating margin −9.7% · Revenue (TTM) 31.8M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −66%, 6236 screens richer than that median.
Fair Value models
Bear4.29 TWDFair Value 4.59 TWDBull4.90 TWD
Price 13.55 TWD · Downside -66.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0087 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−20.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−29.3% (2021) → −2.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +24.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score75 · Top 25%
Fair Value upside−66.1% · Bottom 25%
Profitability
Return on equity (12 months)0.2% · Above median
Return on assets1.9% · Top 25%
Net margin (12 months)1.0% · Above median
Operating margin (12 months)−9.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)−2.3% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B3.65× · Pricier than median
P/S (12 months)17.73× · Priciest 25%
Price / free cash flow (fiscal year)60.8× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)1· sector 0
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 20
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Neith Corporation Fair Value". https://www.fairvalue-calculator.com/stock/6236
Frequently asked questions
Is Neith Corporation (6236) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of 4.59 TWD versus a price of 13.55 TWD, about 66% lower (overvalued).
What is the fair value of 6236?
Our model-based fair value for Neith Corporation is 4.59 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 13.55 TWD.
What is the quality score of 6236?
Neith Corporation has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neith Corporation (6236)?
Our model-based price target is the fair value of 4.59 TWD (as of Nov 10, 2026) from 18 valuation models. Cautious scenario 4.29 TWD, optimistic scenario 4.90 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Neith Corporation stock forecast for 2026?
Our models put fair value at 4.59 TWD, about 66% lower versus a price of 13.55 TWD (overvalued). Cautious scenario 4.29 TWD, optimistic scenario 4.90 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Neith Corporation (6236)?
Neith Corporation reported trailing-twelve-month revenue of about 31.8M TWD (latest available figure, as of Nov 10, 2026).
What growth is priced into Neith Corporation (6236)?
For today's price to be fair in a discounted-cash-flow model, Neith Corporation would have to grow free cash flow by +26.8 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +3.6 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of 6236 use?
Our models discount Neith Corporation at 10.3 %: a base by market capitalisation (nano), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Neith Corporation that is +26.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Neith Corporation (6236) delivered so far?
Over the past 4 years revenue at Neith Corporation grew +3.6 % a year. The price currently implies free-cash-flow growth of +26.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Neith Corporation (6236) growing?
The median revenue growth in the sector is +1.6 % a year. That is the yardstick for the growth priced into Neith Corporation (+26.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Neith Corporation (6236)?
The free-cash-flow yield on the price is 1.65 %: that much free cash flow Neith Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Neith Corporation (6236)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neith Corporation it is 4.59 TWD per share (as of Nov 10, 2026), against a price of 13.55 TWD. It is the blended result of 18 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Neith Corporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6236 trades above its calculated fair value: price 13.55 TWD, fair value 4.59 TWD, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6236?
No. The price is what the market pays today (13.55 TWD); the fair value is what the company's own numbers justify (4.59 TWD). For Neith Corporation the two are 8.96 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Neith Corporation worth?
The market values Neith Corporation at about 564M TWD (market capitalisation, as of Nov 10, 2026). Per share that is 13.55 TWD; our models calculate a fair value of 4.59 TWD per share.
What do the bullish and bearish scenarios say about 6236?
Our models span a range for Neith Corporation: cautious scenario 4.29 TWD, base 4.59 TWD, optimistic 4.90 TWD per share (as of Nov 10, 2026, price 13.55 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neith Corporation (6236)?
Balance-sheet figures for Neith Corporation (as of Nov 10, 2026): return on equity 0.2%. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is 6236 from its 52-week high?
Neith Corporation trades at 13.55 TWD, about 54% below its 52-week high of 29.30 TWD and at the low of 13.55 TWD (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of 4.59 TWD is for.
Which stocks are comparable to Neith Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neith Corporation stock attractive at the current price?
The data as of Nov 10, 2026: price 13.55 TWD, calculated fair value 4.59 TWD (−66%), Quality Score 75/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6236 calculated?
We run Neith Corporation through 18 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 4.59 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Neith Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neith Corporation (6236)?
The closing price on Nov 12, 2026 was 13.55 TWD. Our model-based fair value is 4.59 TWD, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neith Corporation right now?
A high-quality business (quality 75/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (4.90 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (4.29 TWD to 4.90 TWD), unusually little disagreement for a valuation.
Key figures of Neith Corporation
How large is the market capitalisation of Neith Corporation (6236)?
The market capitalisation of Neith Corporation is 564M TWD (≈ $17.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neith Corporation (6236)?
The price-to-sales ratio of Neith Corporation is 22.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neith Corporation (6236)?
Earnings per share at Neith Corporation are 0.0100 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neith Corporation (6236)?
The net margin of Neith Corporation is 1.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neith Corporation (6236)?
The return on equity (ROE) of Neith Corporation is 0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neith Corporation (6236)?
On an EBIT basis the return on assets of Neith Corporation is −13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neith Corporation (6236)?
The operating margin of Neith Corporation is −9.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neith Corporation (6236)?
Revenue at Neith Corporation is growing −2.3% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neith Corporation (6236)?
Earnings per share at Neith Corporation are growing −96.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Neith Corporation in the live analysis
One click puts Neith Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026